RxDoctor Payments Data

Alla Kirzon

Family · Newington, CTNPI 1952841199

Payments from drug & device makers

$593in general payments, 2019–2025

Across 29 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • Agile Therapeutics, Inc.$62
  • AbbVie$58
  • Lilly USA, LLC$42
  • Novo Nordisk$40
  • Abbott$24
  • plus $223 from 12 others

What the payments were for

  • Food & beverage$56094%
  • Other$336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$593 in reported general payments places this provider in the 60th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$115,042
Medicare patients
193
Services billed
1,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$90,925
XareltoRivaroxaban108$35,961
JanuviaSitagliptin Phosphate70$31,952
TrulicityDulaglutide21$26,238
JardianceEmpagliflozin32$20,738
TradjentaLinagliptin58$16,578
NamzaricMemantine Hcl/Donepezil Hcl35$15,145
OzempicSemaglutide12$12,160
Atorvastatin Calcium569$8,975
Breo ElliptaFluticasone/Vilanterol17$7,759
JentaduetoLinagliptin/Metformin Hcl24$7,164
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,064
Lidocaine57$5,340
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$4,905
LumiganBimatoprost15$4,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$22$44,480114 claims
MerckJanuvia$16$31,95270 claims
Lilly USA, LLCTrulicity, Olanzapine$42$28,96536 claims
AbbVieNamzaric, Lumigan$58$19,67650 claims
Novo NordiskOzempic$40$12,16012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,596 family providers in Connecticut.

Other family in Newington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →